Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

C4 Therapeutics Inc

CCCC
Current price
1.55 USD -0.07 USD (-4.32%)
Last closed 1.6 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 78 849 600 USD
Yield for 12 month -81.28 %
Week
Month
Year
CCCC
21.11.2021 - 28.11.2021

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. Address: 490 Arsenal Way, Watertown, MA, United States, 02472

Analytics

WallStreet Target Price

16.3 USD

P/E ratio

Dividend Yield

Current Year

+31 096 000 USD

Last Year

+45 785 000 USD

Current Quarter

+11 072 000 USD

Last Quarter

+2 664 000 USD

Current Year

+31 096 000 USD

Last Year

+45 785 000 USD

Current Quarter

+11 072 000 USD

Last Quarter

+2 664 000 USD

Key Figures CCCC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -137 926 000 USD
Operating Margin TTM -251.16 %
PE Ratio
Return On Assets TTM -22.01 %
PEG Ratio
Return On Equity TTM -50.51 %
Wall Street Target Price 16.3 USD
Revenue TTM 20 349 000 USD
Book Value 4.39 USD
Revenue Per Share TTM 0.42 USD
Dividend Share
Quarterly Revenue Growth YOY 63.9 %
Dividend Yield
Gross Profit TTM -86 745 000 USD
Earnings Share -2.75 USD
Diluted Eps TTM -2.75 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CCCC

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CCCC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CCCC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 3.2847
Price Sales TTM 3.8749
Enterprise Value EBITDA 0.508
Price Book MRQ 0.3627

Financials CCCC

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators CCCC

For 52 weeks

1.23 USD 9.41 USD
50 Day MA 1.7 USD
Shares Short Prior Month 1 906 011
200 Day MA 3.03 USD
Short Ratio 3.18
Shares Short 1 954 547
Short Percent 6.73 %